Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections

被引:24
作者
Wang, Taotao [1 ]
Li, Na [1 ]
Hu, Sasa [1 ]
Xie, Jiao [1 ]
Lei, Jin'e [2 ]
Wang, Yan [1 ]
Zheng, Xiaowei [1 ]
Xing, Jianfeng [3 ]
Dong, Yalin [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 1, Coll Med, Dept Pharm, Xian 710061, Peoples R China
[2] Xi An Jiao Tong Univ, Affiliated Hosp 1, Coll Med, Dept Lab, Xian 710061, Peoples R China
[3] Xi An Jiao Tong Univ, Sch Pharm, Xian 710061, Peoples R China
基金
中国国家自然科学基金;
关键词
trough concentrations; logistical regression; clinical response; CRITICALLY-ILL PATIENTS; STAPHYLOCOCCUS-AUREUS; CLINICAL PHARMACOKINETICS; PROTEIN-BINDING; SERUM; PHARMACODYNAMICS; GLYCOPEPTIDES; VARIABILITY; THERAPY; MODEL;
D O I
10.5414/CP202247
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The objective of this study was to identify the factors influencing trough teicoplanin concentrations (C-min), to investigate the relationship between teicoplanin C-min with efficacy and safety, and to determine a target therapeutic concentration. Methods: An analysis was performed on 95 serum concentrations from 50 patients with gram-positive infections who received teicoplanin treatment. Teicoplanin serum concentrations were measured by high-performance liquid chromatography. Univariate and multivariable analysis were performed to investigate the effect of independent variables on teicoplanin C-min. A logistic regression analysis was used to determine the relationship between teicoplanin C-min and efficacy and safety. Results: Teicoplanin therapy was effective in 74.0% (37/50) of patients, and 10.0% (5/50) of patients exhibited signs of adverse events. Using multivariable linear regression, two covariates were found to be a significant effect on teicoplanin C-min: dosage (mg/kg), and creatinine clearance rate (CLcr). There was no covariate that has a significant impact on the safety of teicoplanin and only teicoplanin C-min has a significant impact on the efficacy of treatment in the logistics regression. The logistics regression analysis showed that teicoplanin Cmin of 10 mg/L was associated with a 79.4% probability of success response. Conclusions: This study highlighted that teicoplanin C-min was strongly influenced by the values of dosage (mg/kg) and CLcr and the teicoplanin C-min range of 10 - 20 mg/L was identified as the therapeutic target with optimum clinical efficacy and safety.
引用
收藏
页码:356 / 362
页数:7
相关论文
共 24 条
[11]   Teicoplanin levels in bone and joint infections: Are standard doses subtherapeutic? [J].
Matthews, Philippa C. ;
Taylor, Alison ;
Byren, Ivor ;
Atkins, Bridget L. .
JOURNAL OF INFECTION, 2007, 55 (05) :408-413
[12]   Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics [J].
Niwa, Takashi ;
Imanishi, Yoshinori ;
Ohmori, Tomofumi ;
Matsuura, Katsuhiko ;
Murakami, Nobuo ;
Itoh, Yoshinori .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2010, 35 (05) :507-510
[13]   Pharmacokinetic-pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies [J].
Nomura, K. ;
Fujimoto, Y. ;
Kanbayashi, Y. ;
Ikawa, K. ;
Taniwaki, M. .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2008, 27 (11) :1141-1143
[14]   Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose [J].
Pea, F ;
Brollo, L ;
Viale, P ;
Pavan, F ;
Furlanut, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (04) :971-975
[15]   Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study [J].
Roberts, J. A. ;
Stove, V. ;
De Waele, J. J. ;
Sipinkoski, B. ;
McWhinney, B. ;
Ungerer, J. P. J. ;
Akova, M. ;
Bassetti, M. ;
Dimopoulos, G. ;
Kaukonen, K. -M. ;
Koulenti, D. ;
Martin, C. ;
Montravers, P. ;
Rellom, J. ;
Rhodes, A. ;
Starr, T. ;
Wallis, S. C. ;
Lipman, J. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2014, 43 (05) :423-430
[16]   CLINICAL PHARMACOKINETICS OF TEICOPLANIN [J].
ROWLAND, M .
CLINICAL PHARMACOKINETICS, 1990, 18 (03) :184-209
[17]  
Sato Masaki, 2006, Journal of Infection and Chemotherapy, V12, P185, DOI 10.1007/s10156-006-0446-y
[18]   Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical features [J].
Seki, Masafumi ;
Yabuno, Kaori ;
Miyawaki, Koji ;
Miwa, Yoshihiro ;
Tomono, Kazunori .
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2012, 4 :71-75
[19]   Teicoplanin population pharmacokinetic analysis in hospitalized patients [J].
Soy, Dolors ;
Lopez, Ester ;
Ribas, Josep .
THERAPEUTIC DRUG MONITORING, 2006, 28 (06) :737-743
[20]   Comparative Efficacy and Safety of Vancomycin versus Teicoplanin: Systematic Review and Meta-Analysis [J].
Svetitsky, Shuli ;
Leibovici, Leonard ;
Paul, Mical .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (10) :4069-4079